Free Trial
NASDAQ:OCS

Oculis Q1 2025 Earnings Results & Report

Oculis logo
$7.61 -0.03 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$7.63 +0.02 (+0.30%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis missed analyst earnings expectations but beat on revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.77 versus the -$0.51 consensus estimate, while revenue of $320 thousand topped the $220 thousand estimate by $100 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Oculis EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Oculis Revenue Results

Actual Revenue
$320 thousand
Expected Revenue
$220 thousand
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Oculis Q1 2025 Earnings FAQ

Oculis (NASDAQ:OCS) reported earnings of -$0.77 per share for Q1 2025, missing the consensus estimate of -$0.51. The report was announced on Thursday, May 8, 2025.

Oculis reported revenue of $320 thousand for Q1 2025, against a consensus estimate of $220 thousand.

Oculis Earnings Headlines

Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Oculis Gains FDA IND Clearance for Privosegtor in Acute MS Relapses
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS) is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations.

Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development.

Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.

View Oculis Profile